ClinicalTrials.gg
CompletedNCT01455597Updated May 9, 2022Results posted

Evaluate Long-Term Safety and Efficacy WC3011 (Estradiol Vaginal Cream)

A Phase 3 interventional study of WC3011 Estradiol Vaginal Cream in Vulvovaginal Atrophy, sponsored by Warner Chilcott. Completed at 64 sites in United States. Open to female participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2022-05-09.

Sponsored by Warner Chilcott (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
309
Allocation
Not applicable
Ages
35 Years and older
Sex
Female
01

Study summary

This is an open-label extension study evaluating the long-term safety and efficacy of WC3011 in non-hysterectomized, healthy, postmenopausal women with vulvovaginal atrophy.

02

Conditions studied

  • Vulvovaginal Atrophy

Keywords

  • Postmenopausal Women
  • Vaginal Dryness
  • Postmenopausal Vulvovaginal Atrophy
03

In context

Lead sponsor

Warner Chilcott is the lead sponsor of 58 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

First submitted before Warner Chilcott became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed Study PR-04409.3 (NCT01400776)

Exclusion criteria

Exclusion Criteria:

Developed any of the following during Study-PR04409.3 or has begun taking hormone therapy other than WC3011:

  • to estrogen and/or progestin therapy
  • Known or suspected premalignant or malignant disease (except successfully treated skin cancers)
  • Manifestation of or treatment for significant cardiovascular disease, stroke or ischemic attack
  • Insulin-dependent diabetes mellitus
  • Smoking ≥ 15 cigarettes daily
  • Uncontrolled hypertension - systolic blood pressure (BP) ≥ 160 mmHG or diastolic ≥ 95 mmHg
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
309 participants (actual)

Study arms

  • Experimental
    WC3011 Estradiol Vaginal Cream

    WC3011 estradiol vaginal cream 3 times a week for up to 40 weeks.

    Drug: WC3011 Estradiol Vaginal Cream

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Endometrial Biopsy Results at Final Visit

    The endometrial biopsy results was categorized as: normal results categorized as atrophic/inactive or proliferative, unsatisfactory with endometrial thickness ≤4 mm and missing biopsy with endometrial thickness ≤4 mm; abnormal results categorized as polyp, hyperplasia, and carcinoma; unknown result categorized as unsatisfactory with endometrial thickness \>4 mm, missing biopsy with endometrial thickness \>4 mm, unsatisfactory without transvaginal ultrasonography (TVU) result and missing biopsy without TVU result. The duration of estradiol exposure was combination of studies PR-04409.3 and PR-04509.

    Time frame: Final Visit (Day closest to Day 281)

Secondary outcomes

  1. Change From Baseline in Participants Self-Assessment of the Symptoms of Vulvovaginal Atrophy (VVA) at Each Post-baseline Timepoints

    Self-Assessment of the symptoms of VVA was evaluated for vaginal dryness, vaginal Itching, dysuria, and dyspareunia by a questionnaire. Questionnaire consisted of 5 questions scaled from 0 to 3 level of intensity, where 0-none indicated symptom not present; 1-mild indicated symptom is present but may be intermittent; does not interfere with your activities or lifestyle; 2-moderate indicated symptom is present, aware of the symptom but activities and lifestyle are only occasionally affected; 3-severe indicated usually aware and bothered by the symptom and have modified your activities and/or lifestyle due to the symptom. Higher score indicated most bothersome symptoms. A negative change from Baseline indicates improvement. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.

    Time frame: Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Weeks 4, 8, 16, 24, 32, 40 and Final Visit (Day closest to Day 281)

  2. Change From Baseline in Vaginal Cytology: Percentage of Superficial Vaginal Cells

    Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.

    Time frame: Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Week 40 and Final Visit (Day closest to Day 281)

  3. Change From Baseline in Vaginal Cytology: Percentage of Parabasal Vaginal Cells

    Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.

    Time frame: Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Week 40 and Final Visit (Day closest to Day 281)

  4. Change From Baseline in Vaginal pH

    Vaginal pH was obtained at final visit of the study. The pH was a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14). A negative change from Baseline indicates improvement. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.

    Time frame: Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Week 40 and Final Visit (Day closest to Day 281)

  5. Change From Baseline as Per Investigator's Assessment of Each of the Signs of VVA

    Investigator's assessment of vaginal health was performed by visual inspection of the vagina with respect to the signs of VVA: atrophy, pallor, vaginal dryness, friability, and petechiae scored on a 4-point scale where: 0=none, 1=mild, 2=moderate, or 3= severe. The negative change from Baseline indicates improvement. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.

    Time frame: Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Week 40 and Final Visit (Day closest to Day 281)

  6. Number of Participants With At Least One Treatment Emergent Adverse Event (TEAE)

    An adverse event is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal (investigational) product, whether or not related to medicinal (investigational) product. TEAE are defined as those AEs with onset date on or after the first dose date of study drug in Study PR-04509, or adverse events that worsen after the first dose date of study drug in Study PR-04509.

    Time frame: Up to Week 40

07

Results

Posted May 9, 2022

Participant flow

Participant flow — Overall Study
MilestonePrevious WC3011 Estradiol Vaginal Cream (2 Times/Week)Previous Vehicle (2 Times/Week)Previous WC3011 Estradiol Vaginal Cream (3 Times/Week)Previous Vehicle (3 Times/Week)
Started1015610052
All-participants-treated population101569952
Completed84488042
Not completed1782010
Withdrew: Adverse event7051
Withdrew: Lack of efficacy0120
Withdrew: Lost to follow-up3021
Withdrew: Withdrew consent6585
Withdrew: Reason not specified1233

Outcome measures

PrimaryNumber of Participants With Endometrial Biopsy Results at Final Visit

The endometrial biopsy results was categorized as: normal results categorized as atrophic/inactive or proliferative, unsatisfactory with endometrial thickness ≤4 mm and missing biopsy with endometrial thickness ≤4 mm; abnormal results categorized as polyp, hyperplasia, and carcinoma; unknown result categorized as unsatisfactory with endometrial thickness \>4 mm, missing biopsy with endometrial thickness \>4 mm, unsatisfactory without transvaginal ultrasonography (TVU) result and missing biopsy without TVU result. The duration of estradiol exposure was combination of studies PR-04409.3 and PR-04509.

Time frame:
Final Visit (Day closest to Day 281)
Reported as:
Count of participants · Participants
Number of Participants With Endometrial Biopsy Results at Final Visit
ParticipantsWC3011 Estradiol Vaginal Cream: Less Than 92 DaysWC3011 Estradiol Vaginal Cream: 92-182 DaysWC3011 Estradiol Vaginal Cream: 183-273 DaysWC3011 Estradiol Vaginal Cream: More Than 273 Days
Normal Biopsy: Atrophic3107166
Normal Biopsy: Proliferative0113
Normal Biopsy: Unsatisfactory With Endometrial Thickness ≤4 mm03448
Normal Biopsy: Missing Biopsy With Endometrial Thickness ≤4 mm11121
Abnormal Biopsy: Polyp0001
Unknown: Unsatisfactory With Endometrial Thickness >4 mm0106
Unknown: Missing Biopsy With Endometrial Thickness >4 mm0001
Unknown: Unsatisfactory Without TVU Result0203
Unknown: Missing Biopsy Without TVU Result3966
SecondaryChange From Baseline in Participants Self-Assessment of the Symptoms of Vulvovaginal Atrophy (VVA) at Each Post-baseline Timepoints

Self-Assessment of the symptoms of VVA was evaluated for vaginal dryness, vaginal Itching, dysuria, and dyspareunia by a questionnaire. Questionnaire consisted of 5 questions scaled from 0 to 3 level of intensity, where 0-none indicated symptom not present; 1-mild indicated symptom is present but may be intermittent; does not interfere with your activities or lifestyle; 2-moderate indicated symptom is present, aware of the symptom but activities and lifestyle are only occasionally affected; 3-severe indicated usually aware and bothered by the symptom and have modified your activities and/or lifestyle due to the symptom. Higher score indicated most bothersome symptoms. A negative change from Baseline indicates improvement. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.

Time frame:
Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Weeks 4, 8, 16, 24, 32, 40 and Final Visit (Day closest to Day 281)
Reported as:
Mean · score on a scale
Change From Baseline in Participants Self-Assessment of the Symptoms of Vulvovaginal Atrophy (VVA) at Each Post-baseline Timepoints
score on a scalePrevious WC3011 Estradiol Vaginal Cream (2 Times/Week)Previous Vehicle (2 Times/Week)Previous WC3011 Estradiol Vaginal Cream (3 Times/Week)Previous Vehicle (3 Times/Week)
Vaginal Dryness-Baseline1.2 ± 0.921.5 ± 0.911.2 ± 0.871.5 ± 1.06
Vaginal Dryness-Change From Baseline to Week 4-0.3 ± 0.71-0.3 ± 0.79-0.3 ± 0.62-0.2 ± 0.61
Vaginal Dryness-Change From Baseline to Week 8-0.4 ± 0.81-0.5 ± 0.80-0.4 ± 0.65-0.4 ± 0.64
Vaginal Dryness-Change From Baseline to Week 16-0.5 ± 0.75-0.6 ± 0.91-0.4 ± 0.72-0.3 ± 0.80
Vaginal Dryness-Change From Baseline to Week 24-0.6 ± 0.80-0.6 ± 0.78-0.3 ± 0.72-0.3 ± 0.85
Vaginal Dryness-Change From Baseline to Week 32-0.5 ± 0.88-0.7 ± 0.75-0.3 ± 0.68-0.4 ± 0.95
Vaginal Dryness-Change From Baseline to Week 40-0.5 ± 0.87-0.6 ± 0.86-0.4 ± 0.78-0.5 ± 0.94
Vaginal Dryness-Change From Baseline to Final Visit-0.4 ± 0.89-0.6 ± 0.89-0.3 ± 0.76-0.5 ± 0.90
Vaginal Itching-Baseline0.6 ± 0.730.5 ± 0.710.5 ± 0.700.5 ± 0.67
Vaginal Itching-Change From Baseline to Week 4-0.3 ± 0.63-0.0 ± 0.66-0.2 ± 0.60-0.0 ± 0.80
Vaginal Itching-Change From Baseline to Week 8-0.2 ± 0.74-0.1 ± 0.64-0.3 ± 0.630.0 ± 0.68
Vaginal Itching-Change From Baseline to Week 16-0.3 ± 0.77-0.0 ± 0.69-0.1 ± 0.700.1 ± 0.47
Vaginal Itching-Change From Baseline to Week 24-0.3 ± 0.74-0.2 ± 0.59-0.2 ± 0.720.0 ± 0.58
Vaginal Itching-Change From Baseline to Week 32-0.2 ± 0.69-0.2 ± 0.64-0.2 ± 0.64-0.1 ± 0.59
Vaginal Itching-Change From Baseline to Week 40-0.3 ± 0.80-0.3 ± 0.66-0.3 ± 0.71-0.0 ± 0.47
Vaginal Itching-Change From Baseline to Final Visit-0.3 ± 0.78-0.3 ± 0.67-0.3 ± 0.71-0.0 ± 0.64
Dysuria-Baseline0.1 ± 0.420.2 ± 0.490.1 ± 0.330.1 ± 0.43
Dysuria-Change From Baseline to Week 4-0.1 ± 0.37-0.0 ± 0.50-0.0 ± 0.25-0.1 ± 0.33
Dysuria-Change From Baseline to Week 8-0.1 ± 0.41-0.0 ± 0.440.0 ± 0.35-0.0 ± 0.20
Dysuria-Change From Baseline to Week 16-0.1 ± 0.41-0.1 ± 0.51-0.0 ± 0.280.0 ± 0.14
Dysuria-Change From Baseline to Week 24-0.1 ± 0.29-0.2 ± 0.47-0.0 ± 0.280.0 ± 0.21
Dysuria-Change From Baseline to Week 32-0.1 ± 0.33-0.1 ± 0.54-0.0 ± 0.290.0 ± 0.22
Dysuria-Change From Baseline to Week 40-0.1 ± 0.30-0.1 ± 0.410.0 ± 0.370.0 ± 0.27
Dysuria-Change From Baseline to Final Visit-0.1 ± 0.32-0.1 ± 0.490.0 ± 0.400.0 ± 0.28
Dyspareunia-Baseline1.3 ± 1.141.3 ± 1.141.2 ± 1.081.6 ± 1.24
Dyspareunia-Change From Baseline to Week 4-0.3 ± 0.69-0.5 ± 0.69-0.2 ± 0.66-0.5 ± 0.80
Dyspareunia-Change From Baseline to Week 8-0.3 ± 0.82-0.5 ± 0.77-0.3 ± 0.63-0.5 ± 1.13
Dyspareunia-Change From Baseline to Week 16-0.5 ± 0.93-0.6 ± 0.85-0.4 ± 0.83-0.5 ± 0.88
Dyspareunia-Change From Baseline to Week 24-0.6 ± 0.96-0.6 ± 0.85-0.4 ± 0.86-0.6 ± 1.01
Dyspareunia-Change From Baseline to Week 32-0.5 ± 0.95-0.7 ± 0.94-0.4 ± 0.78-0.6 ± 0.93
Dyspareunia-Change From Baseline to Week 40-0.6 ± 0.99-0.5 ± 0.82-0.3 ± 0.72-0.7 ± 1.06
Dyspareunia-Change From Baseline to Final Visit-0.5 ± 0.94-0.6 ± 0.91-0.3 ± 0.72-0.6 ± 1.15
SecondaryChange From Baseline in Vaginal Cytology: Percentage of Superficial Vaginal Cells

Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.

Time frame:
Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Week 40 and Final Visit (Day closest to Day 281)
Reported as:
Mean · percentage of superficial cells
Change From Baseline in Vaginal Cytology: Percentage of Superficial Vaginal Cells
percentage of superficial cellsPrevious WC3011 Estradiol Vaginal Cream (2 Times/Week)Previous Vehicle (2 Times/Week)Previous WC3011 Estradiol Vaginal Cream (3 Times/Week)Previous Vehicle (3 Times/Week)
Baseline10.4 ± 11.734.0 ± 7.7216.1 ± 18.773.1 ± 7.99
Change From Baseline to Week 4012.8 ± 21.2617.6 ± 18.210.5 ± 20.6913.9 ± 24.56
Change From Baseline to Final Visit11.0 ± 20.9815.9 ± 17.59-0.2 ± 21.7913.0 ± 23.02
SecondaryChange From Baseline in Vaginal Cytology: Percentage of Parabasal Vaginal Cells

Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.

Time frame:
Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Week 40 and Final Visit (Day closest to Day 281)
Reported as:
Mean · percentage of parabasal cells
Change From Baseline in Vaginal Cytology: Percentage of Parabasal Vaginal Cells
percentage of parabasal cellsPrevious WC3011 Estradiol Vaginal Cream (2 Times/Week)Previous Vehicle (2 Times/Week)Previous WC3011 Estradiol Vaginal Cream (3 Times/Week)Previous Vehicle (3 Times/Week)
Baseline9.7 ± 24.3442.2 ± 41.4612.0 ± 29.2834.2 ± 38.74
Change From Baseline to Week 400.0 ± 20.78-42.2 ± 42.00-1.5 ± 33.28-21.2 ± 36.83
Change From Baseline to Final Visit-0.4 ± 22.30-36.3 ± 43.181.2 ± 34.67-24.0 ± 36.80
SecondaryChange From Baseline in Vaginal pH

Vaginal pH was obtained at final visit of the study. The pH was a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14). A negative change from Baseline indicates improvement. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.

Time frame:
Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Week 40 and Final Visit (Day closest to Day 281)
Reported as:
Mean · score on a scale
Change From Baseline in Vaginal pH
score on a scalePrevious WC3011 Estradiol Vaginal Cream (2 Times/Week)Previous Vehicle (2 Times/Week)Previous WC3011 Estradiol Vaginal Cream (3 Times/Week)Previous Vehicle (3 Times/Week)
Baseline5.5 ± 0.816.2 ± 1.065.4 ± 0.806.1 ± 0.99
Change From Baseline to Week 40-0.3 ± 0.97-1.0 ± 1.24-0.2 ± 1.04-0.8 ± 0.95
Change From Baseline to Final Visit-0.2 ± 1.04-1.0 ± 1.19-0.1 ± 1.08-1.0 ± 1.04
SecondaryChange From Baseline as Per Investigator's Assessment of Each of the Signs of VVA

Investigator's assessment of vaginal health was performed by visual inspection of the vagina with respect to the signs of VVA: atrophy, pallor, vaginal dryness, friability, and petechiae scored on a 4-point scale where: 0=none, 1=mild, 2=moderate, or 3= severe. The negative change from Baseline indicates improvement. Participants at Final visit/Visit 7 included those who were to complete all the evaluations in the study including who prematurely withdrew from the study.

Time frame:
Baseline (Baseline/Visit 1 for this study was the same as Final Visit/Visit 5 for completers of PR-04409.3) to Week 40 and Final Visit (Day closest to Day 281)
Reported as:
Mean · score on a scale
Change From Baseline as Per Investigator's Assessment of Each of the Signs of VVA
score on a scalePrevious WC3011 Estradiol Vaginal Cream (2 Times/Week)Previous Vehicle (2 Times/Week)Previous WC3011 Estradiol Vaginal Cream (3 Times/Week)Previous Vehicle (3 Times/Week)
Atrophy-Baseline1.1 ± 0.701.5 ± 0.761.1 ± 0.691.4 ± 0.80
Atrophy-Change From Baseline to Week 40-0.3 ± 0.79-0.7 ± 0.82-0.3 ± 0.81-0.5 ± 0.77
Atrophy-Change From Baseline to Final Visit-0.2 ± 0.82-0.6 ± 0.80-0.2 ± 0.84-0.6 ± 0.84
Pallor-Baseline1.1 ± 0.781.5 ± 0.831.0 ± 0.741.3 ± 0.77
Pallor-Change From Baseline to Week 40-0.4 ± 0.81-0.8 ± 1.00-0.3 ± 0.79-0.5 ± 0.77
Pallor-Change From Baseline to Final Visit-0.4 ± 0.83-0.6 ± 0.99-0.2 ± 0.82-0.6 ± 0.77
Dryness-Baseline1.0 ± 0.811.4 ± 0.891.0 ± 0.781.1 ± 1.01
Dryness-Change From Baseline to Week 40-0.4 ± 0.73-1.0 ± 0.92-0.4 ± 0.87-0.4 ± 0.86
Dryness-Change From Baseline to Final Visit-0.4 ± 0.75-0.8 ± 0.97-0.3 ± 0.92-0.5 ± 0.94
Friability-Baseline0.4 ± 0.670.6 ± 0.820.3 ± 0.590.5 ± 0.75
Friability-Change From Baseline to Week 40-0.2 ± 0.57-0.5 ± 0.85-0.2 ± 0.67-0.2 ± 0.69
Friability-Change From Baseline to Final Visit-0.2 ± 0.55-0.4 ± 0.88-0.1 ± 0.73-0.3 ± 0.73
Petechiae-Baseline0.3 ± 0.630.6 ± 0.800.2 ± 0.590.4 ± 0.75
Petechiae-Change From Baseline at Week 40-0.1 ± 0.45-0.5 ± 0.80-0.1 ± 0.56-0.1 ± 0.65
Petechiae-Change From Baseline to Final Visit-0.1 ± 0.44-0.5 ± 0.79-0.1 ± 0.54-0.2 ± 0.63
SecondaryNumber of Participants With At Least One Treatment Emergent Adverse Event (TEAE)

An adverse event is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal (investigational) product, whether or not related to medicinal (investigational) product. TEAE are defined as those AEs with onset date on or after the first dose date of study drug in Study PR-04509, or adverse events that worsen after the first dose date of study drug in Study PR-04509.

Time frame:
Up to Week 40
Reported as:
Count of participants · Participants
Number of Participants With At Least One Treatment Emergent Adverse Event (TEAE)
ParticipantsWC3011 Estradiol Vaginal Cream
Number of Participants With At Least One Treatment Emergent Adverse Event (TEAE)195

Adverse events

Collected over Up to Week 40. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
WC3011 Estradiol Vaginal Cream0/308 (0%)8/308 (2.6%)50/308 (16.2%)
Most frequent serious events
Most frequent serious events
EventWC3011 Estradiol Vaginal Cream
CholelithiasisHepatobiliary disorders1/308
Femoral artery occlusionVascular disorders1/308
DysarthriaNervous system disorders1/308
Confusional statePsychiatric disorders1/308
VertigoEar and labyrinth disorders1/308
AppendicitisInfections and infestations1/308
Atrial fibrillationCardiac disorders1/308
PalpitationsCardiac disorders1/308
Transient ischaemic attackNervous system disorders1/308
OsteoarthritisMusculoskeletal and connective tissue disorders1/308
Most frequent other events
Most frequent other events
EventWC3011 Estradiol Vaginal Cream
Vulvovaginal Mycotic InfectionInfections and infestations23/308
Upper Respiratory Tract InfectionInfections and infestations17/308
SinusitisInfections and infestations16/308

Baseline characteristics

All participants who received at least 1 dose of study drug in Study PR-04509.

Age, Continuous
Age, Continuous(years)WC3011 Estradiol Vaginal Cream
Mean59.0 ± 5.54
Sex: Female, Male
Sex: Female, Male(Participants)WC3011 Estradiol Vaginal Cream
Female308
Male0
08

Study locations

64 sites
  • Medical Affiliated Research Center, Inc.
    Huntsville, Alabama 35801, United States
  • Warner Chilcott Investigational Site
    Mobile, Alabama 36608, United States
  • Women's Health Research
    Phoenix, Arizona 85015, United States
  • Precision Trials, LLC
    Phoenix, Arizona 85032, United States
  • Radiant Research-Scottsdale
    Scottsdale, Arizona 85251, United States
  • Radiant Research-Tucson
    Tucson, Arizona 85710, United States
  • Visions Clinical Research-Tucson
    Tucson, Arizona 85712, United States
  • Genesis Center for Clinical Research
    San Diego, California 92103, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • Women's Healthcare Inc.
    San Diego, California 92123, United States
  • Coastal Connecticut Research, LLC
    New London, Connecticut 06320, United States
  • Visions Clinical Research
    Boynton Beach, Florida 33472, United States
  • Women's Medical Research Group, LLC
    Clearwater, Florida 33759, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Miami Research Associates
    Miami, Florida 33143, United States
  • New Age Medical Research Corp
    Miami, Florida 33186, United States
  • Ormond Medical Arts Pharmaceutical Research Center
    Ormond Beach, Florida 32174, United States
  • OB-GYN Specialists of the Palm Beaches
    Palm Beach Gardens, Florida 33410, United States
  • Radiant Research-St. Petersburg
    Pinellas Park, Florida 33781, United States
  • Comprehensive Clinical Trials, LLC
    West Palm Beach, Florida 33409, United States
  • Radiant Research-Atlanta
    Atlanta, Georgia 30342, United States
  • Fellows Research Alliance, Inc.
    Savannah, Georgia 31406, United States
  • Radiant Research-Chicago
    Chicago, Illinois 60654, United States
  • Springfield Clinical, LLP
    Springfield, Illinois 62703, United States
  • The South Bend Clinic, LLP
    Granger, Indiana 46530, United States
  • Radiant Research - Overland Park
    Overland Park, Kansas 66202, United States
  • Heartland Research Associates
    Wichita, Kansas 67207, United States
  • Bluegrass Clinical Research, Inc.
    Louisville, Kentucky 40291, United States
  • York Clinical Consulting
    Marrero, Louisiana 70072, United States
  • Women Under Study
    New Orleans, Louisiana 70115, United States
  • Beyer Research
    Kalamazoo, Michigan 49009, United States
  • Ridgeview Research
    Chaska, Minnesota 55318, United States
  • Affiliated Clinical Research
    Las Vegas, Nevada 89106, United States
  • Office of R. Garn Mabey, M.D.
    Las Vegas, Nevada 89128, United States
  • Lawrence OB-GYN Associates, P.C.
    Lawrenceville, New Jersey 08648, United States
  • Phoenix OB-GYN Assoc., LLC
    Moorestown, New Jersey 08057, United States
  • Women's Health Research Center
    Plainsboro, New Jersey 08536, United States
  • Hawthorne Medical Research, Inc.
    Greensboro, North Carolina 27408, United States
  • Eastern Carolina Women's Center
    New Bern, North Carolina 28562, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • Hawthorne Medical Research, Inc.
    Winston-Salem, North Carolina 27103, United States
  • Lyndhurst Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Rapid Medical Research, Inc.
    Cleveland, Ohio 44122, United States
  • The Columbus Center for Women's Health Research
    Columbus, Ohio 43213, United States
  • Clinical Trials of America, Inc.
    Eugene, Oregon 97401, United States
  • Advanced Clinical Research
    Medford, Oregon 97504, United States
  • Philadelphia Clinical Research, LLC
    Philadelphia, Pennsylvania 19114, United States
  • Clinical Trials Research Services, LLC
    Pittsburgh, Pennsylvania 15206, United States
  • Susan L. Floyd, MD, PC
    Wexford, Pennsylvania 15090, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Fellows Research Alliance, Inc.
    Bluffton, South Carolina 29910, United States
  • Practice Research Organization, Inc.
    Dallas, Texas 75230, United States
  • Radiant Research-Dallas
    Dallas, Texas 75231, United States
  • Research Across America
    Dallas, Texas 75234, United States
  • Advances In Health, Inc
    Houston, Texas 77030, United States
  • Radiant Research-San Antonio
    San Antonio, Texas 78229, United States
  • Center for Reproductive Medicine
    Webster, Texas 77598, United States
  • J. Lewis Research-Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research - Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • Physicians' Research Options LLC
    Sandy, Utah 84070, United States
  • Eastern Virginia Medical School
    Norfolk, Virginia 23507-1627, United States
  • Virginia Women's Center
    Richmond, Virginia 23233, United States
  • Seattle Women's: Health, Research, Gynecology
    Seattle, Washington 98105, United States
  • North Spokane Women's Clinic
    Spokane, Washington 99207, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2011 to primary completion in Dec 2012, 13 months.

Results were first posted in May 2022, 9 years 5 months after primary completion. A results delay was requested in Feb 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2011
First posted
Oct 20, 2011
StartActual
Oct 20, 2011
Primary completionActual
Dec 3, 2012
CompletionActual
Dec 3, 2012
Results delay requested
Feb 14, 2014
Results first posted
May 9, 2022
Last update
May 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01455597
Lead sponsor
Warner Chilcott
Responsible party
Sponsor
First posted
Oct 20, 2011
Start date
Oct 20, 2011
Primary completion
Dec 3, 2012
Completion
Dec 3, 2012
Results posted
May 9, 2022
Last update
May 9, 2022

Study contacts

Anna Chan, PharmD
study director · Allergan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion